Evofem Biosciences (NASDAQ: EVFM) reported Q4 EPS of ($0.58), $0.17 worse than the analyst estimate of ($0.41).

"We are very pleased with the promising results from the AMPOWER trial, which met the agreed-upon primary endpoint," said Saundra Pelletier, Chief Executive Officer of Evofem. "The time is right for Amphora. We haven't seen significant innovation in on-demand women's birth control in almost 20 years and many women are dissatisfied with the current hormonal birth control options. In fact, more than 16 million women are not using any form of birth control, presenting a strong commercial opportunity for Evofem and the women who need new options."

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.